Stellar Biotechnologies gets immunotherapy manufacturing contract
Port Hueneme immunotherapy company Stellar Biotechnologies announced an exclusive multi-year supply agreement with Taiwanese manufacturer Amaran Biotechnology.
The agreement coincides with late-stage clinical studies for an immunotherapy called Adagloxad Simolenin, which treats cancers including metastatic breast cancer. The two companies will also develop the manufacturing process for Stellar’s Keyhole Limpet Hemocyanin conjugated vaccine, made from the blood of a marine animal found off the California coast and an ingredient in the production of the treatment.
Stellar will maintain files with the U.S. Food and Drug Administration recording the purchase of KLH by Amaran, the company said in a statement March 1.
Stellar revenues had fallen 71 percent to $140,000 for the quarter ended Dec. 31, due to a decrease in product sales volumes. Expenses also decreased 13 percent, ending at $1.56 million.
The company’s stock rose 26.8 percent in the days following the announcement, closing at $1.94 Friday, March 3.
• Contact Marissa Nall at email@example.com.